Cargando…

Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma

BRAF inhibitors have changed the standard therapeutic protocol for advanced or metastatic melanoma which harbored notorious BRAF(V600E) single mutation. However, drug resistance to BRAF inhibitors happens just like other cancer treatment. In this study, we constructed the ideal BRAF(V600E)-modeled s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Hsin-Chieh, Chen, Yu-Chian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412490/ https://www.ncbi.nlm.nih.gov/pubmed/25960652 http://dx.doi.org/10.2147/IJN.S80150

Ejemplares similares

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
por: Goodall, Megan L, et al.
Publicado: (2014)

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
por: Krepler, Clemens, et al.
Publicado: (2016)

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
por: Sevilla, Arrate, et al.
Publicado: (2020)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
por: Sigalotti, L, et al.
Publicado: (2011)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
por: Ponti, Giovanni, et al.
Publicado: (2012)

Amelanotic Malignant Melanoma with a BRAF V600E Mutation Mimicking Primary Lung Cancer
por: Matsuzawa, Reiko, et al.
Publicado: (2021)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder
por: Yu, Zhou, et al.
Publicado: (2018)

Gaussian field-based 3D-QSAR and molecular simulation studies to design potent pyrimidine–sulfonamide hybrids as selective BRAF(V600E) inhibitors
por: Singh, Ankit Kumar, et al.
Publicado: (2022)

Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens
por: Løes, Inger Marie, et al.
Publicado: (2014)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
por: Zepeda-Lopez, Priscilla Denise, et al.
Publicado: (2016)

Biological insights into BRAF(V600) mutations in melanoma patient: Not mere therapeutic targets
por: Improta, Giuseppina, et al.
Publicado: (2013)

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy
por: Hannan, Enda J., et al.
Publicado: (2017)

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
por: Jenkins, Molly H., et al.
Publicado: (2015)

Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib
por: Ross, Kayleigh C., et al.
Publicado: (2018)

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition
por: Rowdo, Florencia Paula Madorsky, et al.
Publicado: (2020)

Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene
por: Hall, Arnaldur, et al.
Publicado: (2013)

Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
por: Kocovski, Linda, et al.
Publicado: (2015)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
por: Ebeling, Marcel, et al.
Publicado: (2023)

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
por: Salemi, Rossella, et al.
Publicado: (2018)

Insight on BRAF(V600E) mutated colorectal cancer immune microenvironment
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Differential sensitivity of melanoma cell lines with BRAF(V600E )mutation to the specific Raf inhibitor PLX4032
por: Søndergaard, Jonas N, et al.
Publicado: (2010)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Overexpression of Mcl-1 confers resistance to BRAF(V600E) inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
por: Fofaria, Neel M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t6hp9skt4fkof6o9ngnsvj2id7